Project Grant R21AI189222
- The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $781,367 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Weill Medical College of Cornell University. The grant, awarded on January 25, 2024, will support research to define and maximize the impact of CD8+ T-cell selection on the landscape of HIV integration sites. The goal is to optimize strategies for eradicating the persistent reservoir of HIV-infected cells and achieve...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $824,331 Project Grant to Trustees of Boston College to conduct research on "Understanding Formation and Dynamics of the SIV Reservoir." The research aims to improve understanding of the establishment and persistence of latent viral reservoirs in HIV-infected individuals, particularly the role of naive CD4+ T cells, in...
- This Project Grant award of $149,389, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to characterize the clonal landscape of the HIV reservoir in CD4 cells. The awardee, Weill Medical College of Cornell University, will isolate and culture pure CD4 HIV reservoir clonal populations to phenotypically, genotypically, and functionally analyze them. This includes...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $859,992 Project Grant to Yale University for the "Molecular Investigations of HIV-1 Maturation Pathways and Inhibitor Actions in situ" research project. The grant, funded under NIAID's Allergy and Infectious Diseases Research Program (CFDA 93.855), aims to use advanced in-situ cryo-electron microscopy and tomography techniques to visualize the structural transitions of the HIV-1 virus during the maturation...
- This $624,902 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the impact of the HIV accessory protein Vpr on epigenetic remodeling and viral persistence in myeloid cells. The 5-year project, starting on Apr 23, 2025, will focus on characterizing how Vpr induces epigenetic changes to facilitate sustained HIV transcription and latency reactivation, as well as...
- The University of Chicago was awarded a $295,276 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), to computationally investigate key morphological transitions in the HIV-1 life cycle. The research aims to develop a mechanistic understanding of viral assembly, maturation, and uncoating processes, which could aid in the design of new antiretroviral therapies targeting...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $1,016,951 to The University of Texas MD Anderson Cancer Center to conduct research on reversing the immune system changes that lead to the establishment of the HIV reservoir during antiretroviral therapy (ART) initiation. The goal is to use TGF-beta blockade, combined with broadly neutralizing...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,568,644 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Wistar Institute of Anatomy and Biology, a non-profit biomedical research institute. The award aims to develop an individualized HIV cure strategy that combines enhanced neutralizing antibody responses, antiviral adaptive NK cells, and engineered cell-mediated effector strategies. The goal is to characterize...
- This $243,713 Project Grant awarded on January 27, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program supports research to characterize mechanisms by which HIV-infected macrophages evade antibody-dependent cell-mediated cytotoxicity (ADCC) by natural killer (NK) cells. The objective is to determine how infected macrophages, which serve as a physiologically relevant viral reservoir, resist NK cell...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $862,398 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Fred Hutchinson Cancer Center in Seattle, WA. The grant, running from August 1, 2025 to July 31, 2030, will support research to selectively target and eliminate the HIV/SIV reservoir in T follicular helper cells using novel anti-PD-1 chimeric antigen receptor (CAR) T cells. The research aims to develop safer and more...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $240,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Northwestern University to conduct research on characterizing the HIV-1 viral reservoirs that persist even under antiretroviral therapy (ART). The 2-year project aims to identify the cellular sources and genetic diversity of the HIV-1 reservoirs, as well as study the sources and characteristics of the residual viremia that can lead to rapid viral rebound after therapy cessation. The research will utilize tissue "ex vivo" infections and clinical samples from people living with HIV-1 under ART to comprehensively assess the viral populations produced by different cell types and anatomical compartments. This work seeks to enhance the scientific understanding of HIV-1 reservoir establishment and dynamics, which is critical for developing effective curative strategies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $240.0k | 9/3/25 |